Vermilion Energy, listed on the NYSE as VET, is set to unveil its latest quarterly earnings report on March 6, 2024. Analysts are forecasting an earnings per share (EPS) of $0.52 for the company, and investors are eagerly awaiting to see if Vermilion Energy will exceed this projection and offer positive guidance for the next quarter. It is well known that guidance can have a more significant impact on stock prices than beating or missing earnings estimates.
In the previous quarter, Vermilion Energy fell short of EPS expectations by $0.04, causing a 0.41% drop in share price the following day. Taking a look at the company’s historical performance, we can see a pattern in how past earnings have influenced stock prices:
- Q3 2023: EPS Estimate $0.30, EPS Actual $0.26, Price Change -0.0%
- Q2 2023: EPS Estimate $0.24, EPS Actual $0.58, Price Change 5.0%
- Q1 2023: EPS Estimate $0.70, EPS Actual $1.73, Price Change 4.0%
- Q4 2022: EPS Estimate $0.01, EPS Actual $1.80, Price Change -1.0%
As of March 4, Vermilion Energy’s shares were trading at $11.5, reflecting a 14.85% decrease over the past year. With this downward trend in mind, long-term investors may have a pessimistic outlook leading up to the upcoming earnings release.
On March 5, 2024, VET stock showed some promising signs of improvement despite trading near the bottom of its 52-week range and below its 200-day simple moving average. The price of VET shares increased by $0.15 since the market last closed, representing a 1.30% rise.
Investors may have been encouraged by the positive price momentum of VET on March 5th, as the stock managed to overcome its initial dip and make gains by the end of the trading day. This could indicate a shift in sentiment towards VET, potentially leading to further upward movement in the stock price.
For more information and updates on Vermilion Energy’s earnings announcements, you can check out their earnings calendar on popular financial platforms such as Nasdaq, TipRanks, MarketBeat, and Yahoo Finance.
Vermilion Energy Inc.
VET
Strong Buy
Updated on: 05/03/2024
Financial Health
Very Healthy
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Buy
DCF: Strong Buy
ROE: Sell
Price Target
Current$11.73
Concensus$10.74
Low$10.74
Median$10.74
High$10.74
Social Sentiments
4:00 PM (UTC)
Date:14 February, 2022
Twitter Sentiment
Stocktwits Sentiment
Analyst Ratings
Analyst / firm Rating
Anthony Petrucci Canaccord Genuity Buy
